Comparative effectiveness of combination first-line therapies for metastatic renal cell carcinoma (mRCC).

e16549Background: Numerous immunotherapy (IO) and vascular endothelial growth factor receptor inhibitors (VEGFI) options are approved for first-line (1L) treatment of mRCC. We performed a systemati...